Já chegaram ao Brasil as vacinas para prevenir a infecção pelo HPV.
Há uma centena de tipos de HPV, mas a maioria das infecções é causada por apenas quatro deles. As versões 16 e 18 do vírus são responsáveis por 70% dos casos de câncer de colo de útero. Já os HPV 6 e 11 respondem por 90% das verrugas genitais.
Fabricada pelo laboratório Merck Sharp & Dhome, a Vacina Quadrivalente contra o HPV protege contra quatro tipos do vírus – o 6, 11, 16 e 18 -, que são responsáveis por 70% dos casos de câncer do colo de útero e por 90% das verrugas genitais e está indicada em mulheres entre 9 e 26 anos de idade.
Fabricada pelo laboratório GSK , a Vacina Cervarix, também chamada de Vacina contra HPV oncogênico da GSK, protege contra os vírus 16 e 18. Segundo informações do fabricante, "A vacina demonstrou 100% de eficácia contra as infecções incidentes e persistentes, contra as anormalidades citológicas e o desenvolvimento histológico de NIC associados ao HPV-16 e ao HPV-18.9" Como a anterior, a idade recomendada da vacinação é a mesma.
Ambos os fabricantes apresentam pesquisas suficientes que
mostram uma proteção duradoura nas mulheres vacinadas para o risco de câncer de
útero. Solicitamos que entre em contato com seu médico pessoal para saber as
vantagens da vacina contra HPV.
atualizado em 01 de fevereiro de 2009 06:45:21
HPV é DST !!! Proteja-se
!!! Leia sobre sexo seguro
Leia mais:
Referências da vacina contra os virus 16 e 18:
1.FRANCO, EL. et al. Vaccination against human papillomavirus infection: a new
paradigm in cervical cancer control. Vaccine, 23: 2388-2394, 2005.
2.JUNG W. et al. Strategies against human papillomavirus infection and cervical
cancer. The Journal of Microbiology, 42(4): 255-266, 2004.
3.FEDERAÇÃO BRASILEIRA DAS SOCIEDADES DE GINECOLOGIA E OBSTETRÍCIA.
Papilomavírus humano (HPV): diagnóstico e tratamento. [S.l.], 2002. 19 p.
4.RAMA CH. et al. Detecção sorológica de anti-HPV 16 e 18 e sua associação com
os achados do Papanicolaou em adolescentes e mulheres jovens. Rev Assoc Med Bras,
52(1): 43-47, 2006.
5.INCA - Instituto Nacional do Câncer. Disponível em: http://www.inca.gov.br.
Acesso em: 09 mai. 2007.
6.GINECO - Atenção Integral à Saúde da Mulher. Disponível em:
http://www.gineco.com.br . Acesso em: 09
mai. 2007.
7.MUNOZ N. et al. Against which human papillomavirus types shall we vaccinate
and screen? The international perspective. Int J Cancer, 111: 278-285, 2004.
8.HARPER DM. et al. Sustained efficacy up to 4.5 years of a bivalent L1
virus-like particle vaccine against human papillomavirus types 16 and 18:
follow-up from a randomized control trial. The Lancet, 367: 1247-1255, 2006.
9.HARPER, DM. et al. Efficacy of a bivalent L1 virus-like particle vaccine in
prevention of infection with human papillomavirus types 16 and 18 in young women:
a randomised controlled trial. The Lancet, 364: 1757-1765, 2004.
10.IARC - International Agency for Research on Cancer. Disponível em: http://www.iarc.fr.
Acesso em: 10 mai. 2007.
11.KAUFMANN AM. et al. New paradigm for prevention of cervical cancer. European
Journal of Obstetrics & Gynecology and Reproductive Biology, 130: 25-29, 2007.
12.GIANNINI, SL. et al. Enhanced humoral and memory B cellular immunity using
HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination
(AS04) compared to aluminium salt only. Vaccine, 24: 5937-5949, 2006.
13.GALL, SA. et al. Substantial impact on precancerous lesions and HPV
infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04
candidate vaccine. In: AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING,
98, 2007, Los Angeles. Proceedings... Los Angeles: American Association for
Cancer Research, 2007. Abs.: 4900.
14.SCHWARZ,T.F Human papillomavirus 16/18 candidate vaccine adjuvanted with AS04
and its impact on the incidente of cervical cancer. Expert Rev Obstet Gynecol,2
(3):293-303,2007.
15.Vacina contra HPV oncogênico (16 e 18, recombinante, com adjuvante AS04).
Bula do produto.
16.STAT bite: worldwide cervical and uterine cancer incidence and mortality,
2002. J Natl Cancer Inst, 98(15): 1031, 2006.
17.PARKIN, DM. et al. Global cancer statistics, 2002. CA Cancer J Clin, 55(2):
74–108, 2005.
18.BASEMAN, JG. et al. The epidemiology of human papillomavirus infections. J
Clin Virol, 32(Suppl 1): S16-24, 2005.
19. GRAVITT, PE. et al. Diagnosis and management of oncogenic cervical human
papillomavirus infection. Infect Dis North Am, 19(2): 439-58, 2005.
Referências do Vídeo "O Desenvolvimento da Doença - da infecção por HPV ao
câncer do colo do útero". 1, 4, 5, 9, 10, 11
1.GONÇALVES MAG. et al. Immune Cellular esponse to HPV: Current Concepts. The
Brazilian Journal of Infectious Disease, 8(1): 1-9, 2004.
2.STANLEY M. et al. Immune Response to human papillomavirus. Vaccine, 24(Suppl
1): 16-22, 2006.
3.FUNGEPTGI – Fundacíon Grupo de Estudios de las Patologias del Tracto Genital
Inferior. Disponível em: www.fungeptgi.com. Acesso em: 15 jun. 2007.
4.BOSCH FX. et al. The causal relation between human papillomavirus and cervical
cancer. J Clin Pathol, 55: 244-265, 2002.
5.HILDESHEIM A. et al. Risk factors for rapid-onset cervical cancer. Am J Obstet
Gynecol, 180: 571-577, 1999.
6.DUNN JE. et al. Cervical cancer occurrence in Menphis and Shelby County,
Tennessee, during 25 years of its cervical cytology screening program. Am J
Obstet Gynecol, 150(7): 861-864, 1984.
7.BURGER RA. et al. Human papillomavirus type 18: association with poor
prognosis in early stage cervical cancer. Journal of the National Cancer
Institute, 88(19): 1361-1368, 1996.
Referências da Vacina Quadrivalente:
1. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human
papillomavirus genotype distribution in low-grade cervical lesions: Comparison
by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev.
2005;14:1157–1164.
2. Hatch KD, Berek JS. Intraepithelial disease of the cervix, vagina, and vulva.
In: Berek JS, ed. Novak's Gynecology. 13th ed. Philadelphia, Pa: Lippincott
Williams & Wilkins; 2002:471–505.
3. Minucci D, Cinel A, Insacco E, Oselladore M. Epidemiological aspects of
vaginal intraepithelial neoplasia (VAIN). Clin Exp Obstet Gynecol.
1995;22:36–42.
4. Hoff T, Greene L, Davis J. National Survey of Adolescents and Young Adults:
Sexual Health Knowledge, Attitudes and Experiences. Menlo Park, Calif: Henry J.
Kaiser Family Foundation; 2003:14.
5. World Health Organization. Immunization, Vaccines and Biologicals. Report of
the consultation on human papillomavirus vaccines. Geneva, Switzerland, April
2005. Available at: http://www.who.int/vaccines-documents/DocsPDF05/816screen.pdf.
Accessed March 17, 2006.
6. Bernard H-U, Bosch FX, Campo MS, et al. Human Papillomaviruses. Lyon, France:
International Agency for Research on Cancer; 1995. IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans; Vol 64.
7. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human
papillomavirus infection: Incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218–226.
8. Lazcano-Ponce E, Rivera L, Arillo-Santillán E, Salmerón J, Hernández-Avila M,
Muñoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among
mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 2001;32:243–247.
9. Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of
adolescent human papillomavirus vaccination: A survey of parental attitudes.
Vaccine. 2006;24:3087–3094
10. World Health Organization. Viral cancers. Available at:
http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html.
Accessed September 21, 2006.
11. Hwang MY. Protect against cervical cancer. JAMA. 2000;283:1094.
12. Centers for Disease Control and Prevention. National Center for HIV, STD and
TB Prevention, Division of Sexually Transmitted Diseases. STD prevention:
Genital HPV infection: Fact sheet. Available at: http://www.cdc.gov/std/hpv/STDFact-HPV.htm.
Accessed April 18, 2006.
13. Data on file, MSD_______________.
14. World Health Organization. Sexually transmitted infections increasing–250
million new infections annually. WHO Features [press release]. December
1990;No.152:1–6.
15. Maw RD, Reitano M, Roy M. An international survey of patients with genital
warts: Perceptions regarding treatment and impact on lifestyle. Int J STD AIDS.
1998;9:571–578.
16. McKee MD, Lurio J, Marantz P, Burton W, Mulvihill M. Barriers to follow-up
of abnormal Papanicolaou smears in an urban community health center. Arch Fam
Med. 1999;8:129–134.
17. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19.
18. American Cancer Society. Cancer Facts and Figures 2005. Atlanta, Ga:
American Cancer Society; 2005.
19. World Health Organization, Department of Vaccines and Other Biologicals, and
International Agency for Research on Cancer. The current status of development
of prophylactic vaccines against human papillomavirus infection: Report of a
technical meeting, Geneva, 16–18 February 1999. Geneva, Switzerland: World
Health Organization; 1999.
20. Bonnez W. Papillomavirus. In: Richman DD, Whitley RJ, Hayden FG, eds.
Clinical Virology. New York, NY: Churchill Livingstone; 2002:569–611.
21. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type
distribution and serological response to HPV type 6 virus-like particles in
patients with genital warts. J Clin Microbiol. 1995;33:2058–2063.
22. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital
warts in a set of private health plans in the United States. Clin Infect Dis.
2003;36:1397–1403.
Esta página é oferecida por
|
Copyright © 1997 - 2010,
05 jan 2010
Dr. Sérgio dos Passos Ramos médico especialista em Ginecologia e
Obstetrícia, formado na Universidade Estadual de Campinas - UNICAMP |